These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
777 related articles for article (PubMed ID: 30719026)
1. Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Patente TA; Pinho MP; Oliveira AA; Evangelista GCM; Bergami-Santos PC; Barbuto JAM Front Immunol; 2018; 9():3176. PubMed ID: 30719026 [TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy. Zhu S; Yang N; Wu J; Wang X; Wang W; Liu YJ; Chen J Pharmacol Res; 2020 Sep; 159():104980. PubMed ID: 32504832 [TBL] [Abstract][Full Text] [Related]
3. In-Depth Analysis of the Impact of Different Serum-Free Media on the Production of Clinical Grade Dendritic Cells for Cancer Immunotherapy. Calmeiro J; Mendes L; Duarte IF; Leitão C; Tavares AR; Ferreira DA; Gomes C; Serra J; Falcão A; Cruz MT; Carrascal MA; Neves BM Front Immunol; 2020; 11():593363. PubMed ID: 33613517 [TBL] [Abstract][Full Text] [Related]
4. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs. Truxova I; Pokorna K; Kloudova K; Partlova S; Spisek R; Fucikova J Immunol Lett; 2014 Jul; 160(1):39-49. PubMed ID: 24726860 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells. Lee JM; Shin KS; Koh CH; Song B; Jeon I; Park MH; Kim BS; Chung Y; Kang CY Cancer Lett; 2021 Nov; 520():38-47. PubMed ID: 34224797 [TBL] [Abstract][Full Text] [Related]
6. Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands. Raaijmakers TK; Ansems M Cancer Immunol Immunother; 2018 Nov; 67(11):1789-1796. PubMed ID: 29998375 [TBL] [Abstract][Full Text] [Related]
7. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for Huber A; Dammeijer F; Aerts JGJV; Vroman H Front Immunol; 2018; 9():2804. PubMed ID: 30559743 [TBL] [Abstract][Full Text] [Related]
8. Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions. Verheye E; Bravo Melgar J; Deschoemaeker S; Raes G; Maes A; De Bruyne E; Menu E; Vanderkerken K; Laoui D; De Veirman K Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055096 [TBL] [Abstract][Full Text] [Related]
10. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Galati D; Zanotta S Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963 [TBL] [Abstract][Full Text] [Related]
11. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. Bol KF; Schreibelt G; Gerritsen WR; de Vries IJ; Figdor CG Clin Cancer Res; 2016 Apr; 22(8):1897-906. PubMed ID: 27084743 [TBL] [Abstract][Full Text] [Related]
12. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cell therapy in cancer treatment; the state-of-the-art. Sadeghzadeh M; Bornehdeli S; Mohahammadrezakhani H; Abolghasemi M; Poursaei E; Asadi M; Zafari V; Aghebati-Maleki L; Shanehbandi D Life Sci; 2020 Aug; 254():117580. PubMed ID: 32205087 [TBL] [Abstract][Full Text] [Related]
14. Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy. Peng X; He Y; Huang J; Tao Y; Liu S Front Immunol; 2021; 12():613492. PubMed ID: 33732237 [TBL] [Abstract][Full Text] [Related]
15. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells. Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685 [TBL] [Abstract][Full Text] [Related]
16. The use of dendritic cells for cancer vaccination. Esche C; Shurin MR; Lotze MT Curr Opin Mol Ther; 1999 Feb; 1(1):72-81. PubMed ID: 11249687 [TBL] [Abstract][Full Text] [Related]
17. Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy. van de Ven R; Reurs AW; Wijnands PGJTB; van Wetering S; Kruisbeek AM; Hooijberg E; Scheffer GL; Scheper RJ; de Gruijl TD Cancer Immunol Immunother; 2012 Feb; 61(2):181-191. PubMed ID: 21874304 [TBL] [Abstract][Full Text] [Related]
18. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. van Gulijk M; Dammeijer F; Aerts JGJV; Vroman H Front Immunol; 2018; 9():2759. PubMed ID: 30568653 [TBL] [Abstract][Full Text] [Related]
19. Directing dendritic cell immunotherapy towards successful cancer treatment. Sabado RL; Bhardwaj N Immunotherapy; 2010 Jan; 2(1):37-56. PubMed ID: 20473346 [TBL] [Abstract][Full Text] [Related]